Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Appendicitis
Interventions: UGBRSB, Local Infiltration; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 92
States / cities: Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more

Conditions: Hepatocellular Carcinoma
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 24
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more

Conditions: Postoperative Pain Management
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hemophilia, Hemorrhage, Facelift Surgery
Interventions: 1%Tranexamic acid with standard local, 3% TXA, 1% TXA with local plus 3% TXA-soaked pledgets; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ankle Fractures
Interventions: Regional anesthesia group, Local multimodal analgesia group; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Aging
Interventions: High Flavanol Trial, Low Flavanol Trial, High Flavanol Trial; long-term, Low Flavanol Trial; long-term effects; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Biochemical Recurrent Prostate Cancer
Interventions: Isoflavone; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions: Gabapentin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: ArtemiCoffee; Drug
Lead sponsor: Zin W Myint; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Pain
Interventions: Hydrocodone ER; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 54
States / cities: Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more

Conditions: New Onset Atrial Fibrillation, Anesthesia, Local, Cardiac Disease
Interventions: Ropivacaine 0.2% Injectable Solution; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer, Prostate Cancer
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: capecitabine, irinotecan hydrochloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bladder Cancer
Interventions: BCG strain of Mycobacterium bovis; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Surgery, Anesthesia, Local, Fasting
Interventions: Non-fasting, Fasting; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Migraine
Interventions: lidocaine, bupivicaine and saline, lidocaine plus bupivicaine plus triamcinolone (steroid); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 72 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Fitchburg, Wisconsin

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Anxiety
Interventions: Synera; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Malignant Pleural Mesothelioma
Interventions: Pembrolizumab, IMPRINT; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: FOLFIRI regimen, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, melphalan, hyperthermia treatment; Drug · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Comparison of UGBRS Block and Local Infiltration

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures

Role of Flavanols in Exercise and Aging

Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

ArtemiCoffee in Patients With Rising PSA

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Intravesical BCG Administration to Patients With Invasive Bladder Cancer

Effect of Fasting on Patient Outcomes After Wide-Awake, Local Anesthesia-only, No Tourniquet (WALANT) Procedures

A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Local Field Potentials Recorded From Deep Brain Stimulating (DBS) Electrodes